| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Circulating Tumor DNA | 13 | 2023 | 235 | 5.440 |
Why?
|
| Neoplasms | 107 | 2023 | 15193 | 5.110 |
Why?
|
| Proto-Oncogene Proteins B-raf | 30 | 2023 | 1283 | 4.180 |
Why?
|
| Erdheim-Chester Disease | 11 | 2023 | 53 | 3.650 |
Why?
|
| TOR Serine-Threonine Kinases | 29 | 2024 | 1546 | 3.350 |
Why?
|
| Mutation | 82 | 2023 | 15179 | 3.130 |
Why?
|
| Phosphatidylinositol 3-Kinases | 26 | 2024 | 1678 | 3.040 |
Why?
|
| Cell-Free Nucleic Acids | 8 | 2021 | 224 | 2.840 |
Why?
|
| Molecular Targeted Therapy | 36 | 2020 | 2330 | 2.680 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 62 | 2023 | 15862 | 2.470 |
Why?
|
| Naphthyridines | 3 | 2022 | 41 | 2.390 |
Why?
|
| Protein Kinase Inhibitors | 42 | 2023 | 4757 | 2.380 |
Why?
|
| Urea | 3 | 2022 | 290 | 2.160 |
Why?
|
| Antineoplastic Agents | 48 | 2022 | 14289 | 2.090 |
Why?
|
| DNA, Neoplasm | 8 | 2018 | 1910 | 2.020 |
Why?
|
| Class I Phosphatidylinositol 3-Kinases | 22 | 2021 | 521 | 1.940 |
Why?
|
| Melanoma | 13 | 2023 | 5317 | 1.830 |
Why?
|
| Gastrointestinal Stromal Tumors | 4 | 2022 | 297 | 1.730 |
Why?
|
| Histiocytosis, Sinus | 3 | 2023 | 86 | 1.700 |
Why?
|
| Biomarkers, Tumor | 30 | 2023 | 10331 | 1.620 |
Why?
|
| DNA Mutational Analysis | 17 | 2022 | 2283 | 1.530 |
Why?
|
| Isocitrate Dehydrogenase | 6 | 2022 | 480 | 1.490 |
Why?
|
| Cholangiocarcinoma | 5 | 2023 | 493 | 1.480 |
Why?
|
| Everolimus | 10 | 2021 | 415 | 1.460 |
Why?
|
| Proto-Oncogene Proteins c-akt | 15 | 2024 | 2054 | 1.450 |
Why?
|
| Sirolimus | 14 | 2020 | 814 | 1.450 |
Why?
|
| Liquid Biopsy | 6 | 2023 | 158 | 1.430 |
Why?
|
| Adult | 149 | 2023 | 77950 | 1.410 |
Why?
|
| Bile Duct Neoplasms | 4 | 2023 | 493 | 1.410 |
Why?
|
| High-Throughput Nucleotide Sequencing | 18 | 2019 | 2291 | 1.370 |
Why?
|
| Aged | 140 | 2021 | 70117 | 1.350 |
Why?
|
| Middle Aged | 159 | 2024 | 86204 | 1.340 |
Why?
|
| Humans | 241 | 2024 | 261506 | 1.320 |
Why?
|
| Exanthema | 4 | 2024 | 211 | 1.310 |
Why?
|
| Maximum Tolerated Dose | 23 | 2023 | 1290 | 1.260 |
Why?
|
| Colorectal Neoplasms | 12 | 2023 | 3578 | 1.210 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 15 | 2023 | 5319 | 1.190 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 18 | 2023 | 1331 | 1.170 |
Why?
|
| Female | 171 | 2024 | 141928 | 1.120 |
Why?
|
| Clinical Trials, Phase I as Topic | 20 | 2022 | 604 | 1.120 |
Why?
|
| Proto-Oncogene Proteins c-kit | 5 | 2020 | 479 | 1.120 |
Why?
|
| Histiocytosis, Langerhans-Cell | 7 | 2021 | 261 | 1.090 |
Why?
|
| Male | 146 | 2024 | 123000 | 1.090 |
Why?
|
| Gallbladder Neoplasms | 4 | 2023 | 245 | 1.060 |
Why?
|
| Pyridines | 6 | 2021 | 1244 | 1.050 |
Why?
|
| Skin Neoplasms | 9 | 2021 | 4654 | 1.040 |
Why?
|
| Lung Neoplasms | 21 | 2023 | 11538 | 1.030 |
Why?
|
| Young Adult | 66 | 2021 | 21445 | 1.020 |
Why?
|
| ErbB Receptors | 11 | 2018 | 2295 | 0.960 |
Why?
|
| Receptor, Platelet-Derived Growth Factor alpha | 3 | 2020 | 134 | 0.950 |
Why?
|
| ras Proteins | 12 | 2017 | 770 | 0.930 |
Why?
|
| Dose-Response Relationship, Drug | 25 | 2022 | 4938 | 0.930 |
Why?
|
| Aged, 80 and over | 72 | 2021 | 29902 | 0.920 |
Why?
|
| Clostridium | 2 | 2020 | 25 | 0.890 |
Why?
|
| Bevacizumab | 16 | 2018 | 938 | 0.870 |
Why?
|
| Liquid-Liquid Extraction | 1 | 2021 | 11 | 0.830 |
Why?
|
| Hodgkin Disease | 3 | 2020 | 1429 | 0.830 |
Why?
|
| Precision Medicine | 14 | 2023 | 1154 | 0.820 |
Why?
|
| Antineoplastic Agents, Immunological | 5 | 2022 | 1249 | 0.820 |
Why?
|
| Breast Neoplasms | 19 | 2021 | 15694 | 0.820 |
Why?
|
| Antibodies, Monoclonal, Humanized | 22 | 2023 | 3251 | 0.810 |
Why?
|
| Gastrointestinal Neoplasms | 3 | 2020 | 600 | 0.800 |
Why?
|
| Treatment Outcome | 68 | 2022 | 32848 | 0.790 |
Why?
|
| Spores, Bacterial | 2 | 2020 | 49 | 0.790 |
Why?
|
| Prognosis | 44 | 2022 | 21713 | 0.780 |
Why?
|
| Genomics | 6 | 2019 | 2738 | 0.780 |
Why?
|
| Electron Transport Complex I | 1 | 2021 | 62 | 0.780 |
Why?
|
| Proto-Oncogene Proteins c-met | 7 | 2019 | 419 | 0.760 |
Why?
|
| Cetuximab | 6 | 2016 | 472 | 0.750 |
Why?
|
| Enzyme Inhibitors | 4 | 2022 | 1879 | 0.740 |
Why?
|
| Aminopyridines | 5 | 2021 | 212 | 0.710 |
Why?
|
| Carboplatin | 4 | 2021 | 823 | 0.690 |
Why?
|
| Immunoconjugates | 1 | 2022 | 279 | 0.690 |
Why?
|
| Naltrexone | 2 | 2016 | 87 | 0.680 |
Why?
|
| Paclitaxel | 6 | 2021 | 1996 | 0.670 |
Why?
|
| Piperazines | 3 | 2021 | 2101 | 0.670 |
Why?
|
| PTEN Phosphohydrolase | 8 | 2015 | 986 | 0.660 |
Why?
|
| Histone Deacetylases | 1 | 2020 | 365 | 0.640 |
Why?
|
| Receptors, Opioid, mu | 2 | 2016 | 86 | 0.640 |
Why?
|
| Polymerase Chain Reaction | 9 | 2021 | 3203 | 0.640 |
Why?
|
| Oncogene Protein v-akt | 1 | 2018 | 101 | 0.630 |
Why?
|
| Disease-Free Survival | 28 | 2017 | 10001 | 0.620 |
Why?
|
| Glycine | 4 | 2020 | 289 | 0.620 |
Why?
|
| Pyrimidines | 9 | 2020 | 3518 | 0.590 |
Why?
|
| Drug Resistance, Neoplasm | 11 | 2020 | 5178 | 0.590 |
Why?
|
| Carcinoma, Squamous Cell | 10 | 2021 | 5437 | 0.590 |
Why?
|
| Signal Transduction | 18 | 2023 | 11965 | 0.580 |
Why?
|
| Escherichia coli | 1 | 2023 | 1203 | 0.580 |
Why?
|
| Gene Expression Profiling | 7 | 2018 | 5159 | 0.580 |
Why?
|
| Sarcoma, Ewing | 3 | 2015 | 406 | 0.570 |
Why?
|
| Receptors, Estrogen | 3 | 2020 | 2086 | 0.560 |
Why?
|
| Receptor, ErbB-2 | 8 | 2022 | 2518 | 0.560 |
Why?
|
| Immunotherapy | 8 | 2021 | 3341 | 0.560 |
Why?
|
| Glutarates | 1 | 2016 | 44 | 0.560 |
Why?
|
| Adolescent | 38 | 2021 | 31252 | 0.560 |
Why?
|
| Drug Approval | 1 | 2017 | 178 | 0.560 |
Why?
|
| Brain Neoplasms | 7 | 2021 | 4849 | 0.560 |
Why?
|
| Kaplan-Meier Estimate | 20 | 2021 | 6207 | 0.550 |
Why?
|
| Quinazolines | 7 | 2021 | 923 | 0.530 |
Why?
|
| Receptors, Progesterone | 2 | 2020 | 1392 | 0.530 |
Why?
|
| Proto-Oncogene Proteins | 11 | 2015 | 2488 | 0.530 |
Why?
|
| Liver Neoplasms | 10 | 2019 | 4557 | 0.530 |
Why?
|
| Constipation | 1 | 2016 | 177 | 0.520 |
Why?
|
| Polyethylene Glycols | 5 | 2021 | 615 | 0.520 |
Why?
|
| Protein-Tyrosine Kinases | 3 | 2016 | 1756 | 0.520 |
Why?
|
| Histone Deacetylase Inhibitors | 6 | 2020 | 612 | 0.510 |
Why?
|
| Sarcoma | 6 | 2017 | 1725 | 0.500 |
Why?
|
| GTP Phosphohydrolases | 3 | 2013 | 336 | 0.500 |
Why?
|
| Bone Neoplasms | 5 | 2016 | 2576 | 0.490 |
Why?
|
| Bile Ducts, Intrahepatic | 4 | 2023 | 334 | 0.490 |
Why?
|
| Narcotic Antagonists | 1 | 2015 | 129 | 0.490 |
Why?
|
| Pyrazines | 5 | 2021 | 495 | 0.490 |
Why?
|
| Angiogenesis Inhibitors | 11 | 2020 | 1248 | 0.480 |
Why?
|
| Triazoles | 7 | 2021 | 617 | 0.460 |
Why?
|
| Sulfonamides | 6 | 2020 | 1823 | 0.460 |
Why?
|
| Sodium-Glucose Transporter 1 | 1 | 2013 | 15 | 0.460 |
Why?
|
| Drug Administration Schedule | 15 | 2019 | 3472 | 0.450 |
Why?
|
| Osteosclerosis | 1 | 2013 | 24 | 0.450 |
Why?
|
| Survival Rate | 20 | 2021 | 12221 | 0.450 |
Why?
|
| Receptor, IGF Type 1 | 3 | 2014 | 347 | 0.440 |
Why?
|
| Benzimidazoles | 3 | 2021 | 428 | 0.430 |
Why?
|
| Gene Amplification | 5 | 2022 | 731 | 0.420 |
Why?
|
| Genital Neoplasms, Female | 3 | 2014 | 735 | 0.390 |
Why?
|
| Neoplasm Metastasis | 19 | 2021 | 5112 | 0.380 |
Why?
|
| Pyrroles | 3 | 2021 | 576 | 0.380 |
Why?
|
| Genetic Variation | 2 | 2016 | 2086 | 0.370 |
Why?
|
| Clinical Trials as Topic | 9 | 2020 | 3719 | 0.370 |
Why?
|
| Neoplasm Staging | 21 | 2021 | 13658 | 0.360 |
Why?
|
| Follow-Up Studies | 18 | 2021 | 14889 | 0.360 |
Why?
|
| Mitogen-Activated Protein Kinase Kinases | 3 | 2023 | 371 | 0.360 |
Why?
|
| Hydrazines | 3 | 2021 | 208 | 0.350 |
Why?
|
| Genes, ras | 2 | 2014 | 667 | 0.350 |
Why?
|
| MAP Kinase Signaling System | 6 | 2020 | 848 | 0.340 |
Why?
|
| Bone Marrow Neoplasms | 2 | 2008 | 132 | 0.340 |
Why?
|
| Neoplasm Proteins | 5 | 2018 | 3230 | 0.340 |
Why?
|
| Disease Progression | 12 | 2021 | 6682 | 0.340 |
Why?
|
| Response Evaluation Criteria in Solid Tumors | 5 | 2023 | 160 | 0.340 |
Why?
|
| Leiomyosarcoma | 2 | 2024 | 223 | 0.340 |
Why?
|
| Tumor Suppressor Protein p53 | 8 | 2020 | 3552 | 0.340 |
Why?
|
| Survival Analysis | 13 | 2018 | 9180 | 0.330 |
Why?
|
| Phosphatidylinositol 3-Kinase | 2 | 2022 | 86 | 0.330 |
Why?
|
| Sensitivity and Specificity | 5 | 2021 | 4971 | 0.320 |
Why?
|
| Fatigue | 6 | 2022 | 1239 | 0.320 |
Why?
|
| DNA Methylation | 1 | 2018 | 2669 | 0.320 |
Why?
|
| Deoxycytidine | 3 | 2023 | 1353 | 0.310 |
Why?
|
| DNA | 3 | 2017 | 2693 | 0.310 |
Why?
|
| Injections, Intralesional | 2 | 2020 | 164 | 0.310 |
Why?
|
| Carcinoma, Hepatocellular | 3 | 2015 | 2027 | 0.310 |
Why?
|
| Antibodies, Monoclonal | 7 | 2017 | 4367 | 0.310 |
Why?
|
| Carcinoembryonic Antigen | 1 | 2008 | 222 | 0.300 |
Why?
|
| Retrospective Studies | 27 | 2023 | 37905 | 0.300 |
Why?
|
| Nausea | 4 | 2022 | 525 | 0.290 |
Why?
|
| Triple Negative Breast Neoplasms | 4 | 2018 | 1215 | 0.290 |
Why?
|
| Glucose | 1 | 2013 | 1248 | 0.290 |
Why?
|
| Metformin | 2 | 2024 | 378 | 0.280 |
Why?
|
| Vascular Endothelial Growth Factor A | 7 | 2021 | 1533 | 0.280 |
Why?
|
| Exons | 3 | 2017 | 1328 | 0.280 |
Why?
|
| Genetic Testing | 5 | 2017 | 1589 | 0.280 |
Why?
|
| Quaternary Ammonium Compounds | 2 | 2016 | 67 | 0.280 |
Why?
|
| Histiocytosis, Non-Langerhans-Cell | 2 | 2016 | 25 | 0.280 |
Why?
|
| Membrane Proteins | 3 | 2013 | 2819 | 0.280 |
Why?
|
| Biopsy | 5 | 2017 | 3443 | 0.270 |
Why?
|
| Rare Diseases | 2 | 2020 | 351 | 0.270 |
Why?
|
| Early Detection of Cancer | 4 | 2019 | 1258 | 0.270 |
Why?
|
| Doxorubicin | 5 | 2021 | 3005 | 0.270 |
Why?
|
| Mitogen-Activated Protein Kinases | 2 | 2019 | 639 | 0.270 |
Why?
|
| Morpholines | 2 | 2019 | 289 | 0.270 |
Why?
|
| Albumins | 2 | 2018 | 258 | 0.260 |
Why?
|
| Interferon-alpha | 1 | 2009 | 889 | 0.260 |
Why?
|
| Thiazoles | 3 | 2019 | 726 | 0.260 |
Why?
|
| Trastuzumab | 4 | 2020 | 696 | 0.260 |
Why?
|
| Receptors, Vascular Endothelial Growth Factor | 3 | 2016 | 355 | 0.260 |
Why?
|
| Pyridazines | 2 | 2019 | 293 | 0.260 |
Why?
|
| Autophagy | 1 | 2011 | 927 | 0.250 |
Why?
|
| Ovarian Neoplasms | 4 | 2021 | 4638 | 0.250 |
Why?
|
| Imatinib Mesylate | 3 | 2017 | 1665 | 0.250 |
Why?
|
| Hydroxamic Acids | 3 | 2016 | 442 | 0.250 |
Why?
|
| Interleukin-1alpha | 2 | 2015 | 56 | 0.250 |
Why?
|
| Immunologic Factors | 4 | 2023 | 649 | 0.250 |
Why?
|
| Neovascularization, Pathologic | 3 | 2017 | 1547 | 0.240 |
Why?
|
| Hydrolases | 2 | 2021 | 123 | 0.240 |
Why?
|
| Administration, Oral | 7 | 2021 | 1544 | 0.240 |
Why?
|
| Uteroglobin | 1 | 2004 | 54 | 0.240 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 2 | 2008 | 3639 | 0.230 |
Why?
|
| Benzoxazoles | 1 | 2024 | 41 | 0.230 |
Why?
|
| Pruritus | 1 | 2023 | 87 | 0.230 |
Why?
|
| Camptothecin | 2 | 2016 | 517 | 0.230 |
Why?
|
| Severity of Illness Index | 5 | 2022 | 4320 | 0.220 |
Why?
|
| Adenocarcinoma | 7 | 2016 | 7789 | 0.220 |
Why?
|
| Toll-Like Receptor 7 | 1 | 2022 | 33 | 0.220 |
Why?
|
| Biguanides | 1 | 2022 | 12 | 0.220 |
Why?
|
| Ipilimumab | 2 | 2017 | 710 | 0.220 |
Why?
|
| Real-Time Polymerase Chain Reaction | 2 | 2017 | 1217 | 0.210 |
Why?
|
| Castleman Disease | 2 | 2015 | 69 | 0.210 |
Why?
|
| Clinical Trials, Phase II as Topic | 2 | 2017 | 665 | 0.210 |
Why?
|
| Proportional Hazards Models | 9 | 2017 | 4988 | 0.200 |
Why?
|
| Argininosuccinate Synthase | 1 | 2021 | 54 | 0.200 |
Why?
|
| Axin Protein | 1 | 2021 | 27 | 0.200 |
Why?
|
| Methylation | 1 | 2023 | 597 | 0.200 |
Why?
|
| Diamines | 1 | 2021 | 24 | 0.200 |
Why?
|
| Pyridones | 4 | 2018 | 348 | 0.200 |
Why?
|
| Non-Randomized Controlled Trials as Topic | 1 | 2020 | 38 | 0.190 |
Why?
|
| Sequence Analysis, DNA | 4 | 2017 | 2483 | 0.190 |
Why?
|
| Extracellular Signal-Regulated MAP Kinases | 2 | 2021 | 460 | 0.190 |
Why?
|
| Oxidative Phosphorylation | 1 | 2022 | 253 | 0.190 |
Why?
|
| Adenine | 1 | 2024 | 631 | 0.190 |
Why?
|
| Cytokines | 2 | 2023 | 2809 | 0.190 |
Why?
|
| Neoplastic Cells, Circulating | 2 | 2015 | 607 | 0.190 |
Why?
|
| Indoles | 2 | 2016 | 1009 | 0.190 |
Why?
|
| Neoplasms, Unknown Primary | 1 | 2022 | 192 | 0.180 |
Why?
|
| Mitogen-Activated Protein Kinase 3 | 2 | 2018 | 259 | 0.180 |
Why?
|
| Multivariate Analysis | 5 | 2015 | 4298 | 0.180 |
Why?
|
| Karyopherins | 1 | 2021 | 136 | 0.180 |
Why?
|
| Hepatic Artery | 2 | 2018 | 240 | 0.180 |
Why?
|
| Clonal Evolution | 1 | 2022 | 253 | 0.180 |
Why?
|
| Head and Neck Neoplasms | 4 | 2022 | 3976 | 0.180 |
Why?
|
| Boron Compounds | 1 | 2020 | 59 | 0.180 |
Why?
|
| Vaginal Neoplasms | 1 | 2021 | 152 | 0.180 |
Why?
|
| Mitogen-Activated Protein Kinase 1 | 2 | 2018 | 280 | 0.180 |
Why?
|
| Aniline Compounds | 1 | 2021 | 177 | 0.180 |
Why?
|
| Estrogen Receptor Antagonists | 1 | 2019 | 9 | 0.170 |
Why?
|
| Glioma | 2 | 2021 | 1963 | 0.170 |
Why?
|
| Germ-Line Mutation | 2 | 2016 | 1046 | 0.170 |
Why?
|
| Reproducibility of Results | 4 | 2017 | 6009 | 0.170 |
Why?
|
| Pyrimidinones | 3 | 2016 | 314 | 0.170 |
Why?
|
| United States Food and Drug Administration | 2 | 2017 | 332 | 0.170 |
Why?
|
| Gene Frequency | 2 | 2019 | 1163 | 0.170 |
Why?
|
| Steroids | 1 | 2021 | 356 | 0.170 |
Why?
|
| Receptor, Fibroblast Growth Factor, Type 3 | 1 | 2019 | 62 | 0.170 |
Why?
|
| Vulvar Neoplasms | 1 | 2021 | 236 | 0.170 |
Why?
|
| Health Expenditures | 1 | 2021 | 211 | 0.170 |
Why?
|
| Pyrazoles | 2 | 2019 | 1471 | 0.170 |
Why?
|
| Genotyping Techniques | 1 | 2019 | 166 | 0.170 |
Why?
|
| Pituitary Neoplasms | 1 | 2020 | 203 | 0.160 |
Why?
|
| Drug Eruptions | 1 | 2021 | 256 | 0.160 |
Why?
|
| Receptor, Fibroblast Growth Factor, Type 2 | 1 | 2019 | 96 | 0.160 |
Why?
|
| Tomography, X-Ray Computed | 8 | 2018 | 7551 | 0.160 |
Why?
|
| MCF-7 Cells | 3 | 2017 | 550 | 0.160 |
Why?
|
| Uterine Cervical Neoplasms | 3 | 2014 | 1833 | 0.160 |
Why?
|
| Genes, Neoplasm | 3 | 2014 | 324 | 0.160 |
Why?
|
| Neoplasm Recurrence, Local | 5 | 2021 | 10035 | 0.160 |
Why?
|
| Formaldehyde | 2 | 2015 | 114 | 0.160 |
Why?
|
| Animals | 12 | 2020 | 59536 | 0.160 |
Why?
|
| Quinazolinones | 1 | 2018 | 51 | 0.160 |
Why?
|
| Neoplasms, Germ Cell and Embryonal | 1 | 2021 | 328 | 0.160 |
Why?
|
| Paraffin Embedding | 2 | 2015 | 226 | 0.160 |
Why?
|
| Chondrosarcoma | 1 | 2020 | 216 | 0.160 |
Why?
|
| Thyroid Neoplasms | 2 | 2022 | 1866 | 0.160 |
Why?
|
| Piperidines | 2 | 2021 | 1035 | 0.150 |
Why?
|
| Receptor, Fibroblast Growth Factor, Type 1 | 1 | 2019 | 182 | 0.150 |
Why?
|
| Carcinogenesis | 3 | 2019 | 1026 | 0.150 |
Why?
|
| Analgesics | 1 | 2021 | 390 | 0.150 |
Why?
|
| Thalidomide | 3 | 2016 | 569 | 0.150 |
Why?
|
| Gene Fusion | 1 | 2019 | 209 | 0.150 |
Why?
|
| Glutamates | 2 | 2008 | 130 | 0.150 |
Why?
|
| Feasibility Studies | 2 | 2020 | 2292 | 0.150 |
Why?
|
| Capecitabine | 1 | 2018 | 388 | 0.150 |
Why?
|
| MAP Kinase Kinase 1 | 2 | 2015 | 160 | 0.150 |
Why?
|
| Multiplex Polymerase Chain Reaction | 1 | 2017 | 49 | 0.150 |
Why?
|
| Guanine | 2 | 2008 | 151 | 0.150 |
Why?
|
| Long QT Syndrome | 1 | 2018 | 92 | 0.150 |
Why?
|
| Laxatives | 1 | 2016 | 12 | 0.150 |
Why?
|
| CTLA-4 Antigen | 2 | 2018 | 657 | 0.150 |
Why?
|
| Symptom Assessment | 1 | 2019 | 267 | 0.150 |
Why?
|
| Quality of Life | 2 | 2015 | 4532 | 0.150 |
Why?
|
| Receptors, Cytoplasmic and Nuclear | 1 | 2021 | 591 | 0.140 |
Why?
|
| Tamoxifen | 1 | 2020 | 876 | 0.140 |
Why?
|
| Carcinoma, Large Cell | 1 | 2016 | 94 | 0.140 |
Why?
|
| Histiocytic Disorders, Malignant | 1 | 2016 | 6 | 0.140 |
Why?
|
| Prospective Studies | 7 | 2022 | 12873 | 0.140 |
Why?
|
| Ketoglutaric Acids | 1 | 2016 | 38 | 0.140 |
Why?
|
| Cell-Free System | 1 | 2016 | 150 | 0.140 |
Why?
|
| Purines | 1 | 2018 | 273 | 0.140 |
Why?
|
| Cell Respiration | 1 | 2016 | 52 | 0.140 |
Why?
|
| Dasatinib | 2 | 2017 | 862 | 0.140 |
Why?
|
| Texas | 9 | 2020 | 6311 | 0.140 |
Why?
|
| Patient Positioning | 1 | 2018 | 195 | 0.140 |
Why?
|
| NADP | 1 | 2016 | 96 | 0.140 |
Why?
|
| Estrogen Receptor alpha | 1 | 2020 | 701 | 0.140 |
Why?
|
| Medical Oncology | 3 | 2021 | 1423 | 0.140 |
Why?
|
| Pemetrexed | 3 | 2016 | 102 | 0.140 |
Why?
|
| Psychometrics | 1 | 2020 | 937 | 0.140 |
Why?
|
| Corpus Callosum | 1 | 2016 | 138 | 0.130 |
Why?
|
| Boronic Acids | 2 | 2014 | 362 | 0.130 |
Why?
|
| Parotid Neoplasms | 1 | 2016 | 148 | 0.130 |
Why?
|
| Proteus Syndrome | 1 | 2015 | 2 | 0.130 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 1 | 2020 | 598 | 0.130 |
Why?
|
| Protein Kinases | 1 | 2019 | 874 | 0.130 |
Why?
|
| Checkpoint Kinase 1 | 1 | 2016 | 174 | 0.130 |
Why?
|
| Indazoles | 4 | 2020 | 297 | 0.130 |
Why?
|
| Radiographic Image Interpretation, Computer-Assisted | 1 | 2018 | 361 | 0.130 |
Why?
|
| Genes, erbB-1 | 1 | 2015 | 101 | 0.130 |
Why?
|
| Mood Disorders | 1 | 2016 | 163 | 0.130 |
Why?
|
| Organoplatinum Compounds | 2 | 2015 | 702 | 0.130 |
Why?
|
| Receptors, Androgen | 1 | 2020 | 878 | 0.130 |
Why?
|
| Basal Cell Nevus Syndrome | 1 | 2014 | 18 | 0.130 |
Why?
|
| Benzamides | 2 | 2010 | 1832 | 0.130 |
Why?
|
| Hamartoma Syndrome, Multiple | 1 | 2015 | 37 | 0.130 |
Why?
|
| Histone Demethylases | 1 | 2016 | 144 | 0.130 |
Why?
|
| Neurofibromatosis 2 | 1 | 2014 | 32 | 0.130 |
Why?
|
| Hereditary Breast and Ovarian Cancer Syndrome | 1 | 2014 | 27 | 0.130 |
Why?
|
| Heart Rate | 1 | 2018 | 737 | 0.130 |
Why?
|
| Antibodies, Bispecific | 1 | 2018 | 246 | 0.120 |
Why?
|
| Exosomes | 1 | 2017 | 253 | 0.120 |
Why?
|
| Pathology, Molecular | 1 | 2015 | 128 | 0.120 |
Why?
|
| Hypothyroidism | 1 | 2016 | 204 | 0.120 |
Why?
|
| Disease Management | 2 | 2021 | 1052 | 0.120 |
Why?
|
| Fanconi Anemia | 1 | 2015 | 88 | 0.120 |
Why?
|
| Histiocytosis | 1 | 2014 | 54 | 0.120 |
Why?
|
| Trientine | 1 | 2013 | 11 | 0.120 |
Why?
|
| Leukemia, Myeloid | 1 | 2019 | 941 | 0.120 |
Why?
|
| Carcinoma, Transitional Cell | 1 | 2021 | 962 | 0.120 |
Why?
|
| Aorta | 1 | 2018 | 692 | 0.120 |
Why?
|
| von Hippel-Lindau Disease | 1 | 2015 | 115 | 0.120 |
Why?
|
| Antineoplastic Agents, Phytogenic | 2 | 2015 | 852 | 0.120 |
Why?
|
| Sarcoidosis | 1 | 2015 | 112 | 0.120 |
Why?
|
| B7-H1 Antigen | 1 | 2021 | 1022 | 0.120 |
Why?
|
| Benzodiazepines | 1 | 2015 | 170 | 0.120 |
Why?
|
| Receptor-Like Protein Tyrosine Phosphatases, Class 2 | 1 | 2013 | 17 | 0.120 |
Why?
|
| Stem Cell Transplantation | 1 | 2020 | 1360 | 0.120 |
Why?
|
| Metaplasia | 1 | 2015 | 383 | 0.120 |
Why?
|
| Tuberous Sclerosis | 1 | 2015 | 136 | 0.120 |
Why?
|
| Desmoplastic Small Round Cell Tumor | 1 | 2014 | 86 | 0.120 |
Why?
|
| Li-Fraumeni Syndrome | 1 | 2014 | 158 | 0.120 |
Why?
|
| Urogenital Neoplasms | 1 | 2014 | 108 | 0.110 |
Why?
|
| F-Box Proteins | 1 | 2014 | 96 | 0.110 |
Why?
|
| Cachexia | 1 | 2015 | 161 | 0.110 |
Why?
|
| Neurofibromatosis 1 | 1 | 2014 | 144 | 0.110 |
Why?
|
| Body Weight | 2 | 2015 | 1293 | 0.110 |
Why?
|
| Biliary Tract Neoplasms | 1 | 2015 | 167 | 0.110 |
Why?
|
| Molecular Diagnostic Techniques | 1 | 2015 | 332 | 0.110 |
Why?
|
| Chelating Agents | 1 | 2013 | 127 | 0.110 |
Why?
|
| Cell Line, Tumor | 6 | 2020 | 14551 | 0.110 |
Why?
|
| Adenomatous Polyposis Coli | 1 | 2014 | 221 | 0.110 |
Why?
|
| Erlotinib Hydrochloride | 4 | 2016 | 388 | 0.110 |
Why?
|
| Intracellular Space | 1 | 2013 | 77 | 0.110 |
Why?
|
| Patient Selection | 2 | 2015 | 2055 | 0.110 |
Why?
|
| Mesoderm | 1 | 2015 | 404 | 0.110 |
Why?
|
| Copper | 1 | 2013 | 165 | 0.110 |
Why?
|
| Sleep Wake Disorders | 1 | 2016 | 348 | 0.110 |
Why?
|
| Hypoxia-Inducible Factor 1, alpha Subunit | 1 | 2014 | 376 | 0.110 |
Why?
|
| Research Design | 2 | 2011 | 1544 | 0.110 |
Why?
|
| Salvage Therapy | 1 | 2021 | 2054 | 0.110 |
Why?
|
| Infusions, Intra-Arterial | 3 | 2018 | 171 | 0.110 |
Why?
|
| Tissue Distribution | 3 | 2019 | 875 | 0.110 |
Why?
|
| Combined Modality Therapy | 4 | 2018 | 8865 | 0.110 |
Why?
|
| Carcinoma, Adenoid Cystic | 1 | 2016 | 421 | 0.110 |
Why?
|
| Recurrence | 1 | 2020 | 4758 | 0.110 |
Why?
|
| RNA Interference | 2 | 2015 | 1408 | 0.110 |
Why?
|
| Gastrointestinal Microbiome | 1 | 2021 | 907 | 0.110 |
Why?
|
| Cancer Vaccines | 1 | 2017 | 697 | 0.100 |
Why?
|
| Anemia | 1 | 2017 | 689 | 0.100 |
Why?
|
| Tumor Microenvironment | 1 | 2022 | 2864 | 0.100 |
Why?
|
| Case-Control Studies | 2 | 2019 | 6100 | 0.100 |
Why?
|
| Phenotype | 2 | 2014 | 6295 | 0.100 |
Why?
|
| Gene Expression Regulation, Neoplastic | 8 | 2021 | 8873 | 0.100 |
Why?
|
| Antibodies | 1 | 2015 | 838 | 0.100 |
Why?
|
| Neoplasms, Glandular and Epithelial | 1 | 2016 | 519 | 0.100 |
Why?
|
| Genetic Association Studies | 1 | 2016 | 1084 | 0.100 |
Why?
|
| Drug Design | 1 | 2013 | 375 | 0.100 |
Why?
|
| Patient Reported Outcome Measures | 3 | 2022 | 799 | 0.100 |
Why?
|
| Odds Ratio | 2 | 2014 | 2316 | 0.100 |
Why?
|
| Carcinoma, Pancreatic Ductal | 1 | 2022 | 1724 | 0.100 |
Why?
|
| Multicenter Studies as Topic | 1 | 2012 | 543 | 0.100 |
Why?
|
| Positron-Emission Tomography | 4 | 2015 | 2173 | 0.100 |
Why?
|
| Genetic Predisposition to Disease | 2 | 2016 | 5539 | 0.100 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2018 | 1209 | 0.100 |
Why?
|
| Time Factors | 5 | 2019 | 12926 | 0.090 |
Why?
|
| Colorectal Neoplasms, Hereditary Nonpolyposis | 1 | 2014 | 469 | 0.090 |
Why?
|
| Genes, abl | 1 | 2010 | 110 | 0.090 |
Why?
|
| STAT3 Transcription Factor | 2 | 2014 | 1121 | 0.090 |
Why?
|
| Carcinoma, Lobular | 1 | 2014 | 611 | 0.090 |
Why?
|
| Retreatment | 3 | 2016 | 452 | 0.090 |
Why?
|
| Genotype | 2 | 2015 | 4109 | 0.090 |
Why?
|
| Consensus | 1 | 2014 | 978 | 0.090 |
Why?
|
| Hematologic Neoplasms | 1 | 2021 | 1870 | 0.090 |
Why?
|
| Interleukin 1 Receptor Antagonist Protein | 1 | 2010 | 103 | 0.090 |
Why?
|
| Cell Survival | 2 | 2014 | 3045 | 0.090 |
Why?
|
| Receptor, Platelet-Derived Growth Factor beta | 1 | 2010 | 153 | 0.090 |
Why?
|
| Pancreatic Neoplasms | 3 | 2022 | 5061 | 0.090 |
Why?
|
| Genes, p53 | 1 | 2014 | 1090 | 0.090 |
Why?
|
| Thymoma | 1 | 2013 | 246 | 0.090 |
Why?
|
| Epithelial-Mesenchymal Transition | 1 | 2015 | 973 | 0.090 |
Why?
|
| Patient Participation | 1 | 2013 | 446 | 0.090 |
Why?
|
| DNA Copy Number Variations | 1 | 2016 | 1516 | 0.090 |
Why?
|
| Dendritic Cells | 1 | 2016 | 1085 | 0.090 |
Why?
|
| Injections, Intravenous | 3 | 2018 | 573 | 0.090 |
Why?
|
| Macrophages | 1 | 2016 | 1304 | 0.090 |
Why?
|
| Cell Proliferation | 3 | 2017 | 7226 | 0.090 |
Why?
|
| Logistic Models | 2 | 2016 | 3441 | 0.090 |
Why?
|
| Diarrhea | 2 | 2024 | 686 | 0.090 |
Why?
|
| Niacinamide | 3 | 2017 | 421 | 0.090 |
Why?
|
| Neoplasm Grading | 3 | 2021 | 1742 | 0.080 |
Why?
|
| Xenograft Model Antitumor Assays | 4 | 2020 | 3821 | 0.080 |
Why?
|
| Polymorphism, Single Nucleotide | 3 | 2017 | 4549 | 0.080 |
Why?
|
| Vomiting | 2 | 2021 | 354 | 0.080 |
Why?
|
| Histones | 1 | 2016 | 1466 | 0.080 |
Why?
|
| Diagnosis, Differential | 3 | 2016 | 4744 | 0.080 |
Why?
|
| Urinary Bladder Neoplasms | 1 | 2021 | 2341 | 0.080 |
Why?
|
| HEK293 Cells | 1 | 2013 | 1489 | 0.080 |
Why?
|
| Ubiquitin-Protein Ligases | 1 | 2014 | 854 | 0.080 |
Why?
|
| Child | 10 | 2020 | 29154 | 0.080 |
Why?
|
| Biomarkers | 3 | 2016 | 5047 | 0.080 |
Why?
|
| Remission Induction | 2 | 2015 | 3569 | 0.080 |
Why?
|
| Prednisone | 2 | 2015 | 984 | 0.080 |
Why?
|
| Anti-Bacterial Agents | 1 | 2021 | 2992 | 0.080 |
Why?
|
| Immunohistochemistry | 4 | 2018 | 7548 | 0.080 |
Why?
|
| United States | 4 | 2020 | 15433 | 0.080 |
Why?
|
| Carcinoma, Ductal, Breast | 1 | 2014 | 1216 | 0.080 |
Why?
|
| Imidazoles | 1 | 2013 | 999 | 0.070 |
Why?
|
| Cell Transformation, Neoplastic | 1 | 2016 | 2359 | 0.070 |
Why?
|
| Cell Cycle | 1 | 2013 | 2084 | 0.070 |
Why?
|
| Blotting, Western | 1 | 2013 | 3536 | 0.070 |
Why?
|
| Analgesics, Opioid | 1 | 2016 | 1371 | 0.070 |
Why?
|
| Chemotherapy, Adjuvant | 2 | 2016 | 3890 | 0.070 |
Why?
|
| Stomach Neoplasms | 2 | 2014 | 2278 | 0.070 |
Why?
|
| Flow Cytometry | 1 | 2013 | 3033 | 0.070 |
Why?
|
| Mice | 5 | 2020 | 34495 | 0.070 |
Why?
|
| Glioblastoma | 1 | 2016 | 1797 | 0.070 |
Why?
|
| Insulinoma | 1 | 2005 | 55 | 0.070 |
Why?
|
| Lymphoma | 1 | 2014 | 1467 | 0.070 |
Why?
|
| Leukemia | 1 | 2014 | 1635 | 0.070 |
Why?
|
| Cell Differentiation | 1 | 2016 | 4078 | 0.060 |
Why?
|
| Cell Cycle Proteins | 1 | 2014 | 2045 | 0.060 |
Why?
|
| Kidney Neoplasms | 2 | 2016 | 3022 | 0.060 |
Why?
|
| Mammaglobin A | 1 | 2004 | 14 | 0.060 |
Why?
|
| Recombinant Proteins | 1 | 2009 | 2927 | 0.060 |
Why?
|
| Area Under Curve | 2 | 2015 | 700 | 0.060 |
Why?
|
| Hypoglycemia | 1 | 2005 | 213 | 0.060 |
Why?
|
| Vinblastine | 1 | 2004 | 453 | 0.060 |
Why?
|
| Thrombocytopenia | 2 | 2021 | 846 | 0.060 |
Why?
|
| Survival | 2 | 2013 | 177 | 0.060 |
Why?
|
| Phosphatidylinositols | 1 | 2022 | 60 | 0.060 |
Why?
|
| Apoptosis | 2 | 2017 | 7591 | 0.050 |
Why?
|
| Mechanistic Target of Rapamycin Complex 1 | 1 | 2024 | 265 | 0.050 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 1 | 2020 | 6550 | 0.050 |
Why?
|
| Endometrial Neoplasms | 1 | 2012 | 1341 | 0.050 |
Why?
|
| Carcinoma, Renal Cell | 1 | 2014 | 2326 | 0.050 |
Why?
|
| Pain | 2 | 2022 | 1658 | 0.050 |
Why?
|
| Bortezomib | 2 | 2014 | 543 | 0.050 |
Why?
|
| Phosphorylation | 3 | 2015 | 4804 | 0.050 |
Why?
|
| Adenosine Triphosphate | 1 | 2024 | 571 | 0.050 |
Why?
|
| Syndrome | 2 | 2015 | 1351 | 0.050 |
Why?
|
| Magnetic Resonance Imaging | 5 | 2017 | 7702 | 0.050 |
Why?
|
| Glucocorticoids | 1 | 2005 | 629 | 0.050 |
Why?
|
| Receptor, Notch1 | 1 | 2022 | 218 | 0.050 |
Why?
|
| AMP-Activated Protein Kinases | 1 | 2024 | 413 | 0.050 |
Why?
|
| Biodiversity | 1 | 2021 | 91 | 0.050 |
Why?
|
| Dihydrotestosterone | 1 | 2020 | 118 | 0.050 |
Why?
|
| Topotecan | 1 | 2021 | 239 | 0.050 |
Why?
|
| Italy | 1 | 2021 | 236 | 0.050 |
Why?
|
| Principal Component Analysis | 1 | 2021 | 218 | 0.050 |
Why?
|
| Phenylurea Compounds | 2 | 2014 | 580 | 0.050 |
Why?
|
| Esophageal Neoplasms | 1 | 2014 | 3168 | 0.050 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2008 | 2594 | 0.050 |
Why?
|
| Cohort Studies | 3 | 2020 | 9244 | 0.050 |
Why?
|
| Oncogene Proteins | 1 | 2022 | 354 | 0.050 |
Why?
|
| Active Transport, Cell Nucleus | 1 | 2021 | 323 | 0.050 |
Why?
|
| Income | 1 | 2021 | 222 | 0.050 |
Why?
|
| Cyclin E | 1 | 2022 | 267 | 0.050 |
Why?
|
| Nitriles | 2 | 2015 | 906 | 0.050 |
Why?
|
| Antineoplastic Agents, Hormonal | 1 | 2005 | 840 | 0.040 |
Why?
|
| Risk Factors | 2 | 2017 | 17523 | 0.040 |
Why?
|
| Interleukin-6 | 2 | 2015 | 1038 | 0.040 |
Why?
|
| Mice, Nude | 2 | 2019 | 4307 | 0.040 |
Why?
|
| Cyclophosphamide | 1 | 2006 | 3001 | 0.040 |
Why?
|
| In Situ Hybridization, Fluorescence | 2 | 2015 | 2232 | 0.040 |
Why?
|
| Cricetulus | 1 | 2019 | 205 | 0.040 |
Why?
|
| Child, Preschool | 4 | 2018 | 16273 | 0.040 |
Why?
|
| Neoplasm Invasiveness | 2 | 2018 | 3981 | 0.040 |
Why?
|
| CHO Cells | 1 | 2019 | 311 | 0.040 |
Why?
|
| Human Umbilical Vein Endothelial Cells | 1 | 2019 | 164 | 0.040 |
Why?
|
| Statistics, Nonparametric | 1 | 2021 | 980 | 0.040 |
Why?
|
| Phylogeny | 1 | 2021 | 826 | 0.040 |
Why?
|
| HCT116 Cells | 1 | 2019 | 348 | 0.040 |
Why?
|
| Aromatase Inhibitors | 1 | 2020 | 305 | 0.040 |
Why?
|
| Wnt Signaling Pathway | 1 | 2021 | 430 | 0.040 |
Why?
|
| Disease Susceptibility | 1 | 2021 | 538 | 0.040 |
Why?
|
| Electrocardiography, Ambulatory | 1 | 2018 | 66 | 0.040 |
Why?
|
| Pilot Projects | 2 | 2015 | 2803 | 0.040 |
Why?
|
| Neoplasm, Residual | 1 | 2004 | 1656 | 0.040 |
Why?
|
| Cost of Illness | 1 | 2021 | 498 | 0.040 |
Why?
|
| Cisplatin | 2 | 2021 | 2432 | 0.040 |
Why?
|
| Affect | 1 | 2019 | 288 | 0.040 |
Why?
|
| Ketones | 1 | 2017 | 54 | 0.040 |
Why?
|
| Meningeal Neoplasms | 1 | 2001 | 441 | 0.040 |
Why?
|
| Estradiol | 1 | 2020 | 748 | 0.040 |
Why?
|
| Elafin | 1 | 2017 | 34 | 0.040 |
Why?
|
| MAP Kinase Kinase Kinase 2 | 1 | 2017 | 14 | 0.040 |
Why?
|
| Furans | 1 | 2017 | 104 | 0.040 |
Why?
|
| Cancer Care Facilities | 2 | 2012 | 884 | 0.040 |
Why?
|
| MAP Kinase Kinase Kinase 1 | 1 | 2017 | 43 | 0.040 |
Why?
|
| Longitudinal Studies | 1 | 2022 | 1945 | 0.040 |
Why?
|
| Therapies, Investigational | 1 | 2017 | 62 | 0.040 |
Why?
|
| Mice, Inbred NOD | 1 | 2019 | 905 | 0.040 |
Why?
|
| Estrogens | 1 | 2020 | 751 | 0.040 |
Why?
|
| Surveys and Questionnaires | 2 | 2021 | 5687 | 0.040 |
Why?
|
| Bacteria | 1 | 2021 | 611 | 0.040 |
Why?
|
| Medical Records | 1 | 2017 | 415 | 0.030 |
Why?
|
| Patient Outcome Assessment | 1 | 2017 | 245 | 0.030 |
Why?
|
| Receptor, trkA | 1 | 2015 | 35 | 0.030 |
Why?
|
| Decompression, Surgical | 1 | 2016 | 143 | 0.030 |
Why?
|
| Memory | 1 | 2019 | 429 | 0.030 |
Why?
|
| Maintenance Chemotherapy | 1 | 2016 | 202 | 0.030 |
Why?
|
| Snail Family Transcription Factors | 1 | 2015 | 120 | 0.030 |
Why?
|
| Metabolic Clearance Rate | 1 | 2015 | 231 | 0.030 |
Why?
|
| Skin | 1 | 2021 | 1259 | 0.030 |
Why?
|
| Artifacts | 1 | 2018 | 532 | 0.030 |
Why?
|
| Hospice Care | 1 | 2016 | 156 | 0.030 |
Why?
|
| GRB10 Adaptor Protein | 1 | 2014 | 19 | 0.030 |
Why?
|
| Mice, SCID | 1 | 2019 | 1869 | 0.030 |
Why?
|
| Zinc Finger E-box-Binding Homeobox 1 | 1 | 2015 | 159 | 0.030 |
Why?
|
| Ghrelin | 1 | 2015 | 79 | 0.030 |
Why?
|
| Alleles | 1 | 2021 | 2437 | 0.030 |
Why?
|
| Mice, Inbred BALB C | 1 | 2019 | 2314 | 0.030 |
Why?
|
| Cranial Irradiation | 1 | 2016 | 315 | 0.030 |
Why?
|
| Metastasectomy | 1 | 2016 | 200 | 0.030 |
Why?
|
| Codon | 1 | 2014 | 241 | 0.030 |
Why?
|
| Receptors, Fibroblast Growth Factor | 1 | 2014 | 153 | 0.030 |
Why?
|
| F-Box-WD Repeat-Containing Protein 7 | 1 | 2014 | 83 | 0.030 |
Why?
|
| Proto-Oncogene Proteins c-bcl-6 | 1 | 2014 | 125 | 0.030 |
Why?
|
| Adrenal Cortex Hormones | 1 | 2017 | 544 | 0.030 |
Why?
|
| Ceruloplasmin | 1 | 2013 | 35 | 0.030 |
Why?
|
| Risk Assessment | 2 | 2018 | 6869 | 0.030 |
Why?
|
| Patient Safety | 1 | 2019 | 649 | 0.030 |
Why?
|
| Protein Stability | 1 | 2015 | 370 | 0.030 |
Why?
|
| Bendamustine Hydrochloride | 1 | 2014 | 107 | 0.030 |
Why?
|
| Nitrogen Mustard Compounds | 1 | 2014 | 73 | 0.030 |
Why?
|
| Radionuclide Imaging | 1 | 2015 | 660 | 0.030 |
Why?
|
| Genetic Counseling | 1 | 2016 | 380 | 0.030 |
Why?
|
| Hospices | 1 | 2013 | 51 | 0.030 |
Why?
|
| Clone Cells | 1 | 2015 | 555 | 0.030 |
Why?
|
| Tissue Fixation | 1 | 2013 | 136 | 0.030 |
Why?
|
| Demography | 1 | 2014 | 435 | 0.030 |
Why?
|
| Vascular Endothelial Growth Factor Receptor-2 | 1 | 2014 | 272 | 0.030 |
Why?
|
| raf Kinases | 1 | 2013 | 81 | 0.030 |
Why?
|
| GTP-Binding Protein alpha Subunits | 1 | 2013 | 34 | 0.030 |
Why?
|
| GTP-Binding Protein alpha Subunits, Gq-G11 | 1 | 2013 | 52 | 0.030 |
Why?
|
| Leptin | 1 | 2015 | 295 | 0.030 |
Why?
|
| Academic Medical Centers | 1 | 2016 | 672 | 0.030 |
Why?
|
| Taxoids | 1 | 2016 | 967 | 0.030 |
Why?
|
| Proteolysis | 1 | 2015 | 370 | 0.030 |
Why?
|
| Necrosis | 1 | 2014 | 580 | 0.030 |
Why?
|
| Janus Kinases | 1 | 2014 | 174 | 0.030 |
Why?
|
| Amino Acid Substitution | 1 | 2014 | 644 | 0.030 |
Why?
|
| Inflammation Mediators | 1 | 2015 | 423 | 0.030 |
Why?
|
| Dogs | 1 | 2014 | 1155 | 0.030 |
Why?
|
| MicroRNAs | 2 | 2017 | 2947 | 0.030 |
Why?
|
| Polymorphism, Genetic | 1 | 2018 | 1450 | 0.030 |
Why?
|
| Valproic Acid | 1 | 2014 | 263 | 0.030 |
Why?
|
| Infusions, Intravenous | 1 | 2015 | 1382 | 0.030 |
Why?
|
| Bone Density Conservation Agents | 1 | 2014 | 198 | 0.030 |
Why?
|
| Cadherins | 1 | 2015 | 660 | 0.030 |
Why?
|
| Arteriovenous Fistula | 1 | 2013 | 92 | 0.030 |
Why?
|
| Proteasome Endopeptidase Complex | 1 | 2014 | 589 | 0.030 |
Why?
|
| Weight Gain | 1 | 2015 | 464 | 0.030 |
Why?
|
| Receptor Protein-Tyrosine Kinases | 1 | 2015 | 661 | 0.030 |
Why?
|
| Mutation Rate | 1 | 2012 | 223 | 0.020 |
Why?
|
| Regression Analysis | 1 | 2014 | 1546 | 0.020 |
Why?
|
| Drug Synergism | 1 | 2014 | 1313 | 0.020 |
Why?
|
| Programmed Cell Death 1 Receptor | 1 | 2018 | 1048 | 0.020 |
Why?
|
| Cell Line | 1 | 2019 | 5114 | 0.020 |
Why?
|
| Radiotherapy, Adjuvant | 1 | 2016 | 2231 | 0.020 |
Why?
|
| Weight Loss | 1 | 2015 | 627 | 0.020 |
Why?
|
| Esophagogastric Junction | 1 | 2014 | 543 | 0.020 |
Why?
|
| RNA | 1 | 2015 | 1013 | 0.020 |
Why?
|
| Antigens, CD | 1 | 2015 | 1385 | 0.020 |
Why?
|
| Exome | 1 | 2016 | 1239 | 0.020 |
Why?
|
| Transfection | 1 | 2015 | 2944 | 0.020 |
Why?
|
| Blood Cell Count | 1 | 2010 | 225 | 0.020 |
Why?
|
| Gastrointestinal Hemorrhage | 1 | 2013 | 340 | 0.020 |
Why?
|
| Homeodomain Proteins | 1 | 2015 | 1143 | 0.020 |
Why?
|
| Oncogene Proteins, Fusion | 1 | 2014 | 755 | 0.020 |
Why?
|
| Whole Body Imaging | 1 | 2010 | 114 | 0.020 |
Why?
|
| Tumor Burden | 1 | 2015 | 1987 | 0.020 |
Why?
|
| Energy Metabolism | 1 | 2015 | 992 | 0.020 |
Why?
|
| Bone Marrow Transplantation | 1 | 2014 | 1581 | 0.020 |
Why?
|
| Decision Support Techniques | 1 | 2014 | 622 | 0.020 |
Why?
|
| Carcinoma, Neuroendocrine | 1 | 2015 | 716 | 0.020 |
Why?
|
| Prevalence | 1 | 2016 | 3260 | 0.020 |
Why?
|
| Analysis of Variance | 1 | 2013 | 2307 | 0.020 |
Why?
|
| Lung | 1 | 2019 | 3151 | 0.020 |
Why?
|
| Referral and Consultation | 1 | 2013 | 899 | 0.020 |
Why?
|
| Immunosuppressive Agents | 1 | 2014 | 1375 | 0.020 |
Why?
|
| Genetic Therapy | 1 | 2015 | 1616 | 0.020 |
Why?
|
| Incidence | 1 | 2017 | 5673 | 0.020 |
Why?
|
| Genome, Human | 1 | 2014 | 1869 | 0.020 |
Why?
|
| Hypertension | 1 | 2015 | 1503 | 0.020 |
Why?
|
| Rats | 1 | 2014 | 6086 | 0.020 |
Why?
|
| Cross-Sectional Studies | 1 | 2014 | 4314 | 0.020 |
Why?
|
| Fluorodeoxyglucose F18 | 1 | 2010 | 1226 | 0.020 |
Why?
|
| Lymph Nodes | 1 | 2015 | 2967 | 0.010 |
Why?
|
| Algorithms | 1 | 2014 | 3890 | 0.010 |
Why?
|
| Transcription Factors | 1 | 2015 | 5270 | 0.010 |
Why?
|
| DNA-Binding Proteins | 1 | 2014 | 4821 | 0.010 |
Why?
|
| Carcinoma | 1 | 2011 | 2578 | 0.010 |
Why?
|
| Predictive Value of Tests | 1 | 2006 | 4892 | 0.010 |
Why?
|